LDL-cholesterol targets after the ACC/AHA 2013 guidelines

Journal of the American College of Cardiology

Volumn 64, Issue 5, 2014, Pages 495-497

  Ben Yehuda, Ori ^a   Demaria, Anthony N ^b  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

guidelines; LDL cholesterol; LDL cholesterol goal; statins

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; BLACK PERSON; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG TARGETING; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GENE; HEALTH CARE ORGANIZATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; INDIVIDUALIZATION; MEDICAL RESEARCH; META ANALYSIS (TOPIC); METHODOLOGY; NOTE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SELECTION; PCSK9 GENE; POST HOC ANALYSIS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SEX DIFFERENCE; TREATMENT OUTCOME;

GUIDELINES; LDL-CHOLESTEROL; LDL-CHOLESTEROL GOAL; STATINS;

ATHEROSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84905190238     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.05.020     Document Type: Editorial

References (16)

1. The 1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure Arch Intern Med 148 1988 1023 1038
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
3. S.M. Grundy, J.I. Cleeman, and C.N. Merz et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
4. N.J. Stone, J. Robinson, and A.H. Lichtenstein et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2889 2934
5. American Association of Clinical Endocrinologists. Letter. Available at: https://www.aace.com/sites/all/files/Member-Alert-Re-Guidelines-112113.pdf. Accessed May 1, 2014.
6. National Lipid Association. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Available at: https://www.lipid.org/nla/2013-accaha-guideline-treatment-blood- cholesterol-reduce-atherosclerotic-cardiovascular-risk. Accessed May 1, 2014.
7. S.M. Boekholdt, G.K. Hovingh, and S. Mora et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials J Am Coll Cardiol 64 2014 485 494
8. V. Ramjee, L.S. Sperling, and T.A. Jacobson Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math J Am Coll Cardiol 58 2011 457 463
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
10. J.R. Downs, M. Clearfield, and S. Weis et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
11. J. Hsia, J.G. MacFadyen, and J. Monyak et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) J Am Coll Cardiol 57 2011 1666 1675
12. D. Morrone, W.S. Weintraub, and P.P. Toth et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials Atherosclerosis 223 2012 251 261
13. K.E. Berge, L. Ose, and T.P. Leren Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy Arterioscler Thromb Vasc Biol 26 2006 1094 1100
14. C.M. Ballantyne, A.G. Olsson, and T.J. Cook et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S Circulation 104 2001 3046 3051
15. C.P. Cannon, R.P. Giugliano, and M.A. Blazing et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes Am Heart J 156 2008 826 832
16. M.J. Pencina, A.M. Navar-Boggan, and R.B. D'Agostino Sr. et al. Application of new cholesterol guidelines to a population-based sample N Engl J Med 370 2014 1422 1431